Atlas Trials

CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Clinical trial NCT02168907 · TERMINATED

Trial details

NCT number
NCT02168907
Sponsor
Wake Forest University Health Sciences
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
B-cell Adult Acute Lymphoblastic LeukemiaB-cell Chronic Lymphocytic LeukemiaCutaneous B-cell Non-Hodgkin LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueIntraocular LymphomaNodal Marginal Zone B-cell LymphomaRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Adult Grade III Lymphomatoid Granulomatosis
Start date
2014-12-01
Primary completion
2015-02-01
Enrollment
1

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.